References

  1. Comprehensive Cervical Cancer Control. A guide to essential practice. Second edition. WHO 2014. Google Scholar

  2. Jacques Ferlay, Hai-Rim Shin, Freddie Bray, David Forman, Colin Mathers , Donald Maxwell Parkin. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-2917. PubMed | Google Scholar

  3. International Agency for Research on Cancer. WHO. GLOBOCAN 2012 . Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Google Scholar

  4. Beaulieu N, Bloom D, Bloom R, Stein R. Breakaway: the Global Burden of Cancer-Challenges and Opportunities; A Report from the Economist Intelligence Unit. 2009. The Economist. Google Scholar

  5. John RM, Ross H. Economic value of disability-adjusted life years lost to cancers. 2008. Google Scholar

  6. Bernard W, STEWART , Christopher P WILD. World Cancer Report 2014: International Agency For Research on Cancer. World Health Organization. Google Scholar

  7. Global Risk Network of the World Economic Forum (2010). Global Risks 2010: A Global Risk Network Report. Geneva. World Economic Forum. Google Scholar

  8. Human papillomavirus (HPV) and cervical cancer. Updated November 2014. Google Scholar

  9. Joseph Monsonego. Infections à papillomavirus : état des connaissances, pratiques et prévention vaccinale. Springer-Verlag Paris. 2006. Google Scholar

  10. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005 Sep; 15(5):727-46. PubMed | Google Scholar

  11. Sue J Goldie, Lynne Gaffikin, Jeremy D, Goldhaber-Fiebert, Amparo Gordillo-Tobar, Carol Levin, Cédric Mahé, Thomas C. Wright, Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. N Engl J Med. 2005; 353(20):2158-68. PubMed | Google Scholar

  12. Mohammed Adnane Tazi, Abdelouahed Er-Raki, Noureddine Benjaafar. Cancer incidence in Rabat, Morocco: 2006-2008. Ecancer. 2013; 7:338. PubMed | Google Scholar

  13. Sanaa El Majjaoui. Cancer du col utérin ; Expérience de l'Institut National d'Oncologie à propos de 646 cas: Caractéristiques épidémiologiques, cliniques, diagnostiques, thérapeutiques et pronostiques. Thèse de doctorat en médecine, Faculté de Médecine et de Pharmacie de Rabat ; Université Mohammed V. 2011. PubMed | Google Scholar

  14. Elske van den Akker-van Marle M, Marjolein van Ballegooijen, Gerrit J van Oortmarssen, Rob Boer, Dik F Habbema J. Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies. J Natl Cancer Inst. 2002 Feb 6; 94(3):193-204. PubMed | Google Scholar

  15. J van Rosmalen, IMCM de Kok, M van Ballegooijen. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG. 2012; 119(6): 699-709. PubMed | Google Scholar

  16. Jane J Kim PhD, Sue J Goldie MD MPH. Health and Economic Implications of HPV Vaccination in the United States. N Engl J Med. 2008; 359(8):821-32. PubMed | Google Scholar

  17. Andrea M Anonychuk, Chris T Bauch, Maraki Fikre Merid, Georges Van Kriekinge, Nadia Demarteau. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health. 2009; 9:401. PubMed | Google Scholar